Journey Medical Presents Phase 1 DFD-29 Clinical Trial Data

Journey Medical Corporation announced positive results from their Phase 1 clinical trial of DFD-29, aimed at treating rosacea. The trial, which involved 60 healthy volunteers over a 16-week period, met all primary objectives without significant safety issues and indicated no negative effects on skin, gastrointestinal, or vaginal microbiota. The company is now awaiting U.S. FDA review for the drug’s approval.

Dr. Srinivas Sidgiddi presented the findings at the American Academy of Dermatology's 2024 Annual Meeting, highlighting that DFD-29 could be used safely for up to 16 weeks. The clinical trial assessed microbiological samples from the skin, stool, and vagina, confirming the drug's safety and tolerability.

Journey Medical’s CEO Claude Maraoui expressed optimism that DFD-29, upon approval, could significantly impact rosacea treatment for millions of patients, providing both anti-inflammatory and anti-redness benefits. The study employed a double-blind, placebo-controlled design, ensuring rigorous data collection and analysis.

Rosacea is a chronic skin condition affecting over 16 million Americans, often causing significant emotional and social hardships for patients. The condition typically manifests in adults between 30 and 50 years old with symptoms like facial redness, inflammatory lesions, and spider veins.

Journey Medical focuses on dermatological treatments and markets various FDA-approved prescription products through an effective sales model. The company was founded by Fortress Biotech and continues to expand its portfolio to address common skin ailments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!